Rifampicin
Braveds
Description
| Product Name | Rifampicin |
| Types | S homologous reagent |
| Form | Crystalline powder |
| CAS NO | 13292-46-1 |
| Producer | China |
| Application | protein synthesis | interferes |
| Purity | >=97% (HPLC), powder |
| Storage | -20°C |
| Recertification | 4Years |
| Synonyms |
Overview
| Dissolubility | chloroform: soluble50 mg/mL |
| Dissolubility | DMSO: soluble100 mg/mL |
| Dissolubility | H2O: soluble2.5 mg/mL at 25°C (pH 7.3) |
| Dissolubility | H2O: soluble1.3 mg/mL (pH 4.3) |
| Content | >=97% (HPLC) |
| Antibacterial spectrum | mycobacteria |
| Antibacterial spectrum | Gram-positive bacteria |
| Antibacterial spectrum | viruses |
| Antibacterial spectrum | Gram-negative bacteria |
| Color | faint-orange to red-brown |
| Storage | -20°C |
| Form | powder |
| Mechanism | protein synthesis | interferes |
General description.
Chemical structure: macrolides.
Biochemical / physiological behavior.
Rifampicin inhibits the assembly of DNA and proteins into mature viral particles. It inhibits the initiation of RNA synthesis by binding to the β-subunit of RNA polymerase, resulting in cell death.
Mode of action: inhibit the initiation of RNA synthesis by binding to the β-subunit of RNA polymerase.
Inhibit the assembly of DNA and protein into mature virus particles.
Application.
Rifampicin is used to treat tuberculosis and tuberculosis-related mycobacterial infections. It is widely used as an antipruritic in autoimmune cholestatic liver disease and primary biliary cirrhosis (PBC). It has been shown to cause hepatitis.
Add to cart
| SKU | UNIT | PRICE (USD) | QTY |
|---|---|---|---|
| SG81242-1G | 1G | 28.1 | |
| SG81242-5G | 5G | 49.4 |
